SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.

(Amendment No.)*							
			Cyclacel Pharmaceuticals, Inc.				
			(Name of Issuer)				
			Common Stock, \$0.001 par value per share				
			(Title of Class of Securities)				
			23254L108				
			(CUSIP Number)				
			October 7, 2010				
			(Date of Event Which Requires Filing of this Statement)				
Check the ap	propriate	e box to	designate the rule pursuant to which this Schedule is filed:				
0	Rule	13d-1(t					
X	Rule	13d-1(c					
0	Rule	13d-1(c					
			r page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for containing information which would alter the disclosures provided in a prior cover page.				
			the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of abject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).				
(,							
CUSIP No. 2	23254L1	.08	13G				
(1)			oorting Persons res International				
	Cupita	Ventu	aco international				
(2)	Check	Check the Appropriate Box if a Member of a Group (See Instructions)					
	(a)	0					
	(b)	0					
(3)	SEC U	se Only	y				
(4)		Citizenship or Place of Organization Cayman Islands					
	Cayilla	11 151411	us				
Number of		(E)	Solo Voting Dover				
Shares		(5)	Sole Voting Power 0				
Beneficially Owned by							
Each		(6)	Shared Voting Power **				
Reporting Person With			2,464,065				
1 (13011 441(11							
		(7)	Sole Dispositive Power				

0

		(8)	Shared Dispositive Power ** 2,464,065		
(9)	Aggreg 2,464,0		nount Beneficially Owned by Each Reporting Person		
(10)	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o				
(11)	Percent of Class Represented by Amount in Row (9) 5.4%				
(12)	Type of Reporting Person (See Instructions) CO				
** Heights Contract these shares.	apital M	anagen	nent, Inc. is the investment manager to Capital Ventures International and as such may exercise voting and dispositive power over		
CUSIP No. 2	23254L1	.08	13G		
(1)	Names of Reporting Persons Heights Capital Management, Inc.				
(2) Check the Appropriate Box if a Member of a Group (See Instructi					
	(a) (b)	0			
(3)	SEC U	se Only	T		
(4)	Citizenship or Place of Organization Delaware				
		(5)	Sole Voting Power 0		
Number of Shares Beneficially Owned by Each Reporting Person With		(6)	Shared Voting Power ** 2,464,065		
		(7)	Sole Dispositive Power 0		
		(8)	Shared Dispositive Power ** 2,464,065		
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person 2,464,065				
(10)	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o				
(11)	Percent of Class Represented by Amount in Row (9) 5.4%				

(12)	Type CO	e of Reporting Person (See Instructions)		
** Heights (Management, Inc. is the investment manager to Capital Ventures International and as such may exercise voting and dispositive power over		
		3		
CUSIP No.	23254]	L108 13G		
Item 1.				
1,011	(a)	Name of Issuer		
	(b)	Cyclacel Pharmaceuticals, Inc. Address of Issuer's Principal Executive Offices		
		200 Connell Drive, Ste. 1500, Berkeley Heights, NJ, 07922		
Item 2(a).		Name of Person Filing This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of Common Stock of the Company, \$0.001 par value per share (the "Shares").		
		(i) Capital Ventures International		
		(ii) Heights Capital Management, Inc.		
Item 2(b).		Address of Principal Business Office or, if none, Residence The address of the principal business office of Capital Ventures International is:		
		One Capitol Place		
		P.O Box 1787 GT Grand Cayman, Cayman Islands		
		British West Indies		
		The address of the principal business office of Heights Capital Management, Inc. is:		
		101 California Street, Suite 3250 San Francisco, California 94111		
Item 2(c).		Citizenship Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.		
Item 2(d)		Title of Class of Securities Common Stock, \$0.001 par value per share		
Item 2(e)		CUSIP Number 23254L108		
Item 3.	If th	is statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:		
	(a)	o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).		
	(b)	o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).		
	(c)	o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).		
	(d)	o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).		
	(e)	o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);		
	(f)	o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);		
	(g)	o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);		
	(h)	o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company

(i)

(j)

Act of 1940 (15 U.S.C. 80a-3);

A non-U.S. institution in accordance with $\S 240.13d-1(b)(1)(ii)(J)$;

§ 240.13d–1(b)(1)(ii)(J), please specify the type of institution:					
		4			
CUSIP I	CUSIP No. 23254L108 13G				
Item 4.	Ownershi	p			
Provide	the following info	ormation regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.			
		required by Items $4(a) - (c)$ is set forth in Rows $5 - 11$ of the cover page for each Reporting Person hereto and is incorporated ce for each such Reporting Person.			
	"Option"). The rare not exercise by mentioned in this Affiliates and any	hares reported as beneficially owned consists of (i) 1,642,710 Shares and (ii) an option to purchase 821,355 Shares (the number of Shares reported as beneficially owned does not include (i) warrants to purchase 821,355 shares of Common Stock that le within 60 days of the date of this report, (ii) warrants to purchase 410,677 shares of Common Stock, which warrants are issuable the Reporting Person of the Option, or (iii) warrants to purchase 215,695 shares of Common Stock. None of the warrants a paragraph are exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its y other Persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of the Exchange Act, would exceed 4.99%.			
	as of August 12,	Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2010 states that there were 36,950,549 Shares outstanding 2010. The Shares outstanding used to calculate the percentage of Shares reported as beneficially owned by the Reporting Persons 8,323,190 shares reported as issued by the Company on the Company's Current Report on Form 8-K dated October 7, 2010.			
	owner of all Shar	Management, Inc., which serves as the investment manager to Capital Ventures International, may be deemed to be the beneficial res owned by Capital Ventures International. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such retheir pecuniary interest therein.			
Item 5.	Ownershi	p of Five Percent or Less of a Class			
		iled to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent check the following: o			
Item 6.	Ownershi	p of More than Five Percent on Behalf of Another Person			
	Not applicable.				
Item 7.	Identificat or Contro	tion and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company I Person			
	Not applicable.				
Item 8.	Identifica	tion and Classification of Members of the Group			
	Not applicable				
Item 9.	Notice of l	Dissolution of Group			
		5			
CUSIP I	No. 23254L108	13G			
Item 10	. Certificati	ion			
	By signing below not held for the pu	veach of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired propose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not as a participant in any transaction having that purpose or effect.			

Exhibit I: Joint Filing Agreement, dated as of October 18, 2010, by and among Capital Ventures International and Heights Capital Management, Inc.

Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

SIGNATURES

Exhibits:

(k) o

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: October 18, 2010

CAPITAL VENTURES INTERNATIONAL

HEIGHTS CAPITAL MANAGEMENT, INC.

By: Heights Capital Management, Inc. pursuant to a Limited Power of Attorney Bv: /s/ Brian Sopinsky Name: Brian Sopinsky Title Secretary

/s/ Brian Sopinsky

Name: Brian Sopinsky Title Secretary

The Limited Power of Attorney executed by Capital Ventures International, authorizing Heights Capital Management, Inc. to sign and file this Schedule 13G on its behalf, which was filed with the Schedule 13G filed with the Securities and Exchange Commission on December 1, 2006 by Capital Ventures International and Heights Capital Management, Inc. with respect to the common stock of Discovery Laboratories, Inc., is hereby incorporated by reference.

6

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Cyclacel Pharmaceuticals, Inc., \$0.001 par value per share is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated as of October 18, 2010

CAPITAL VENTURES INTERNATIONAL

HEIGHTS CAPITAL MANAGEMENT, INC.

By: Heights Capital Management, Inc.

pursuant to a Limited Power of Attorney

/s/ Brian Sopinsky Bv: Name: Brian Sopinsky Secretary

By: /s/ Brian Sopinsky

Title

Name: Brian Sopinsky Title Secretary